Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mars 2018 08h00 HE | Source: Arch Biopartners

Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing

TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the...
27 févr. 2018 07h30 HE | Source: Arch Biopartners

Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced CSBio of Menlo Park,...
16 févr. 2018 09h00 HE | Source: Arch Biopartners

Arch Biopartners Closes Convertible Note Financing

TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX-V:ARCH) (OTCBB:ACHFF) announced it has closed the non-brokered, unsecured convertible note (“Note”)...
13 févr. 2018 08h00 HE | Source: Arch Biopartners

Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage

TORONTO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) a portfolio based biotechnology company, announced today the investigator...
08 févr. 2018 07h30 HE | Source: Arch Biopartners

Arch Biopartners Arranges Convertible Note Financing

TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
26 janv. 2018 08h50 HE | Source: Arch Biopartners

Arch Biopartners Announces Non Brokered Private Placement Financing

TORONTO, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio based biotechnology company, intends to complete a non-brokered private...
06 déc. 2017 10h08 HE | Source: Arch Biopartners

Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial

TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) today announced that the good manufacturing practice (GMP) production...
01 nov. 2017 10h09 HE | Source: Arch Biopartners

Arch Biopartners Engages Nucro Technics to Begin Toxicology Studies for Metablok

TORONTO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro...
24 oct. 2017 08h00 HE | Source: Arch Biopartners Inc.

Arch Biopartners Closes Convertible Note Financing

TORONTO, ONTARIO--(Marketwired - Oct. 24, 2017) - Arch Biopartners Inc., ("Arch" or the "Company") (TSX VENTURE:ARCH)(OTCBB:ACHFF), announced it has closed a non-brokered, unsecured...
10 oct. 2017 06h30 HE | Source: Arch Biopartners Inc.

Arch Biopartners Initiates Manufacturing Process for Metablok

TORONTO, ONTARIO--(Marketwired - Oct. 10, 2017) - Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced it...

Page précédente